At a Glance
- Companies: Swedish Orphan Biovitrum (Sobi); Arthrosi Therapeutics
- Locations: Stockholm, Sweden (Sobi); San Diego, California, USA (Arthrosi)
- Deal value: $950m upfront; up to $550m in milestones; total up to $1.5bn
- Focus area: Chronic and progressive gout, via URAT1 inhibitor pozdeutinurad (AR882)
- Next steps: Close in H1 2026; advance AR882 through phase 3 and potential registration
What happened?
Swedish Orphan Biovitrum (Sobi) has agreed to acquire U.S.‑based Arthrosi Therapeutics in a deal valued at up to $1.5 billion. Under the terms, Sobi will pay $950 million in upfront cash, with up to $550 million in additional payments tied to clinical, regulatory and sales milestones. The transaction is expected to close in the first half of 2026, subject to customary closing conditions and antitrust review.
Why does it matter?
Gout affects millions worldwide and can progress to painful, tophaceous disease despite first‑line urate‑lowering therapy. Arthrosi’s lead asset, pozdeutinurad (AR882), is an oral URAT1 inhibitor that has shown strong uric‑acid‑lowering and tophus‑dissolution signals in phase 2, positioning it as a potential best‑in‑class option for progressive gout. For Sobi, the acquisition deepens its gout portfolio and creates a clear growth driver through the mid‑2030s and beyond.
Who’s behind it?
Sobi is a rare‑disease‑focused biopharma with a growing presence in gout and other chronic inflammatory conditions. Arthrosi is a clinical‑stage biotech developing AR882 for progressive and tophaceous gout, with two phase 3 trials fully enrolled and readouts expected in 2026. Sobi plans to fund the upfront via debt, including existing credit lines and a new facility, and expects the deal to be highly accretive to mid‑ and long‑term growth.
How was it achieved?
The deal centres on AR882’s mechanism: blocking URAT1 in the kidney to increase uric‑acid excretion and sustain lower serum uric‑acid levels, which may dissolve tophi and reduce flares in refractory patients. Sobi will take over development and global commercialisation, leveraging its rare‑disease and specialty‑care infrastructure to accelerate regulatory filings and market access once phase 3 data mature.
What’s next?
Sobi will integrate Arthrosi’s team and pipeline, advance AR882 through phase 3 and potential approvals, and prepare for launch in key markets. The company also expects to report additional late‑stage data for its existing gout assets, creating a broader portfolio that could capture a larger share of the chronic gout market.
What are people saying?
Sobi CEO Guido Oelkers described the acquisition as a way to “expand our gout pipeline with a highly differentiated new asset” and said AR882 has the potential to become the therapy of choice for patients whose symptoms persist despite first‑line treatment. Arthrosi founder and CEO Litain Yeh welcomed the partnership, noting that Sobi’s global commercial expertise will help bring pozdeutinurad to patients more quickly.